🇺🇸 FDA

Company profile · Sponsor

Alexion

Alexion Europe SAS

E35EAD7 · EMA pharma EU
Pipeline
24
Drugs
0
Patents
0

Quick answer

Alexion (E35EAD7) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E35EAD7
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (24)

Search pipeline →

  1. ALXN 2040, ALXN 2040

    Alexion

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  2. ALXN1720 Placebo Product, Gefurulimab

    Alexion

    Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)

    phase 3 small molecule active

    1 trial

  3. ALXN1850 placebo product, ALXN1850

    Alexion

    Hypophosphatasia

    phase 3 small molecule active

    1 trial

  4. ALXN1850, ALXN1850 placebo product

    Alexion

    hypophosphatasia

    phase 3 small molecule active

    1 trial

  5. ALXN1850, Strensiq 40 mg/ml Solution for Injection, Strensiq 100 mg/ml Solution for Injection

    Alexion

    Hypophosphatasia

    phase 3 small molecule active

    1 trial

  6. ALXN2220 Placebo Product, Recombinant human anti-ATTR immunoglobulin G1 (IgG1) monoclonal antibody (mAb)

    Alexion

    Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).

    phase 3 small molecule active

    1 trial

  7. Anti C5 Complement mAb Placebo, Ultomiris 1,100 mg/11 mL concentrate for solution for infusion

    Alexion

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  8. Anti C5 Complement mAb Placebo, Ultomiris 300 mg/30 mL concentrate for solution for infusion

    Alexion

    Hematopoietic stem cell transplant-associated thrombotic microangiopathy

    phase 3 small molecule active

    1 trial

  9. Gefurulimab

    Alexion

    Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)

    phase 3 small molecule active

    1 trial

  10. Placebo for AZP-3601 Pen A and Pen B, AZP-3601, CALCIUM ARROW 500 mg, comprimé à sucer, AZP-3601, UN-ALFA 0,50 microgramme, capsule molle, ROCALTROL 0,25 microgramme, capsule molle

    Alexion

    Hypoparathyroidism

    phase 3 small molecule active

    1 trial

  11. SODIUM CHLORIDE , CAEL-101

    Alexion

    Stage IIIb cardiac AL amyloidosis

    phase 3 small molecule active

    1 trial

  12. SODIUM CHLORIDE , CAEL-101

    Alexion

    stage IIIa cardiac AL amyloidosis

    phase 3 small molecule active

    1 trial

  13. Ultomiris 1,100 mg/11 mL concentrate for solution for infusion

    Alexion

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    1 trial

  14. Ultomiris 1,100 mg/11 mL concentrate for solution for infusion, Anti C5 Complement mAb Placebo

    Alexion

    Delayed Graft Function after Kidney Transplantation

    phase 3 small molecule active

    1 trial

  15. Ultomiris 300 mg/3 mL concentrate for solution for infusion

    Alexion

    Neuromyelitis Optica Spectrum Disorder (NMOSD)

    phase 3 small molecule active

    1 trial

  16. Ultomiris 300 mg/30 mL concentrate for solution for infusion

    Alexion

    Hematopoietic stem cell transplant-associated thrombotic microangiopathy(HSCT- TMA)

    phase 3 small molecule active

    1 trial

  17. Ultomiris 300 mg/30 mL concentrate for solution for infusion, Soliris 300 mg concentrate for solution for infusion, ALXN 2040

    Alexion

    Patients with Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  18. ALXN 2040, Placebo matching ALXN2040

    Alexion

    Geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD)

    phase 2 small molecule active

    1 trial

  19. ALXN 2050, ALXN2050 Placebo Tablets

    Alexion

    Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)

    phase 2 small molecule active

    1 trial

  20. ALXN2420, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, LANREOTIDE ACETATE, LANREOTIDE ACETATE, matching placebo for ALXN2420, LANREOTIDE ACETATE, OCTREOTIDE ACETATE

    Alexion

    Acromegaly

    phase 2 small molecule active

    1 trial

  21. Alxn1920 placebo product, ALXN1920

    Alexion

    Primary Mebranous Nephropathy (PMN)

    phase 2 small molecule active

    1 trial

  22. Rapamune 1 mg/mL oral solution, Rapamune 0.5 mg coated tablets, Co-Trimoxazole Forte 160/800mg Tablets, Rapamune 2 mg coated tablets, adeno-associated virus, serotype 9 (AAV9), PREDNISONE VIATRIS 5 mg, comprimé sécable, PREDNISONE VIATRIS 1 mg, comprimé, PREDNISONE VIATRIS 20 mg, comprimé sécable, Prednisone Olikla 2.5 mg tablety, Prednisone Olikla 10 mg tablety, Prednisone Olikla 50 mg tablety, Rapamune 1 mg coated tablets

    Alexion

    BAG3 Mutation Associated Dilated Cardiomyopathy

    phase 2 small molecule active

    1 trial

  23. Tarperprumig Placebo, Tarperprumig

    Alexion

    Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis

    phase 2 small molecule active

    1 trial

  24. Ultomiris 300 mg/30 mL concentrate for solution for infusion, Concentrate for solution for infusion

    Alexion

    Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is Alexion?

Alexion (E35EAD7) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Alexion sponsor?

We track 24 ClinicalTrials.gov-linked programs for Alexion, including ALXN 2040, ALXN 2040 and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Alexion company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.